Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ESR1 | P03372 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.47 |
| ▸ | HBB | P68871 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | TK1 | P04183 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26296051 | 1.00 | LMNA (0.62) | LMNASMN1; SMN2MAPTESR1ALB | |
| SCHEMBL3437131 | 1.00 | LMNA (0.62) | LMNASMN1; SMN2MAPTESR1ALB | |
| SCHEMBL21345305 | 1.00 | LMNA (0.62) | LMNASMN1; SMN2MAPTESR1ALB | |
| SCHEMBL8104286 | 1.00 | LMNA (0.62) | LMNASMN1; SMN2MAPTESR1ALB | |
| Phosphoric Acid SCHEMBL7906707 | 0.95 | LMNA (0.57) | LMNASMN1; SMN2MAPTESR1ALB | |
| SCHEMBL21345988 | 0.87 | LMNA (0.47) | LMNASMN1; SMN2MAPTESR1ALB | |
| SCHEMBL19657129 | 0.85 | LMNA (0.48) | LMNASMN1; SMN2ALBALDH1A1MAPK1 | |
| SCHEMBL23485 | 0.85 | LMNA (0.58) | LMNAALBALDH1A1TSHRPMP22 | |
| SCHEMBL14596607 | 0.85 | LMNA (0.58) | LMNAALBALDH1A1TSHRPMP22 | |
| SCHEMBL22992337 | 0.85 | LMNA (0.58) | LMNAALBALDH1A1TSHRPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| EP-3105243-B1 | 2',3'-DIDEOXY-5-FLUOROURIDINE DERIVATIVES, A PROCESS FOR THE MANUFACTURE THEREOF AND APPLICATION THEREOF | ADAM MICKIEWICZ UNIV (PL) | 2018-02-21 | — | — | EP | claimed |
| EP-3105243-A1 | 2',3'-DIDEOXY-5-FLUOROURIDINE DERIVATIVES, A PROCESS FOR THE MANUFACTURE THEREOF AND APPLICATION THEREOF | Adam Mickiewicz University (PL) | 2016-12-21 | — | — | EP | claimed |
| EP-3105242-A1 | 2',5'-DIDEOXY-5-FLUOROURIDINE DERIVATIVES HAVING CYTOTOXIC ACTIVITY, A PROCESS FOR THE MANUFACTURE THEREOF AND APPLICATION THEREOF | Adam Mickiewicz University (PL) | 2016-12-21 | — | — | EP | claimed |
| US-9388209-B2 | 2′, 3′-dideoxy-5-fluorouridine derivatives, a process for the manufacture thereof and application thereof | ADAM MICKIEWICZ UNIVERSITY (PL) | 2016-07-12 | — | — | US | claimed |
| US-20160152655-A1 | 2', 3'- DIDEOXY-5-FLUOROURIDINE DERIVATIVES, A PROCESS FOR THE MANUFACTURE THEREOF AND APPLICATION THEREOF | ADAM MICKIEWICZ UNIVERSITY (PL) | 2016-06-02 | — | — | US | claimed |
| WO-2015050467-A1 | 2',3'-DIDEOXY-5-FLUOROURIDINE DERIVATIVES, A PROCESS FOR THE MANUFACTURE THEREOF AND APPLICATION THEREOF | ADAM MICKIEWICZ UNIVERSITY (PL) | 2015-04-09 | — | — | WO | claimed |
| WO-2015041550-A1 | 2',5'-DIDEOXY-5-FLUOROURIDINE DERIVATIVES HAVING CYTOTOXIC ACTIVITY, A PROCESS FOR THE MANUFACTURE THEREOF AND APPLICATION THEREOF | ADAM MICKIEWICZ UNIVERSITY (PL) | 2015-03-26 | — | — | WO | claimed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | claimed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | claimed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | claimed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| EP-1361227-A2 | [5-carboxamide or 5-fluoro]-[2', 3'-unsaturated or 3'-modifield]-pyrimidine nucleosides | Emory University (US) | 2003-11-12 | — | — | EP | claimed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | claimed |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-01-02 | — | — | US | disclosed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | disclosed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | LMNA 3677/4885SMN1; SMN2 2496/4885MAPT 3539/4885 |
| US-11858953-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885SMN1; SMN2 3259/4885MAPT 1468/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885SMN1; SMN2 3259/4885MAPT 1468/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | LMNA 1794/4885SMN1; SMN2 3259/4885MAPT 1468/4885 |
| US-20160152655-A1 | 2', 3'- DIDEOXY-5-FLUOROURIDINE DERIVATIVES, A PROCESS FOR THE MANUFACTURE THEREOF AND APPLICATION THEREOF | DUT, DCK, UGT1A8 | LMNA 1428/4885SMN1; SMN2 3405/4885MAPT 4500/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | LMNA 3677/4885SMN1; SMN2 2496/4885MAPT 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.